Blood tests for lymphoma using small RNA markers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at tiny blood molecules called microRNAs to see if they can help diagnose non-Hodgkin's lymphoma. If you are newly diagnosed and have no other cancers, your blood test results may be compared to known patterns to improve diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with non-Hodgkin's lymphoma confirmed by tissue biopsy
- You are between 18 and 75 years old
- You have not started anti-cancer (neoplastic) treatment yet
- You do not have any other type of cancer now or in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study uses special lab testing (“omics”) on people with certain fast-growing B-cell lymphomas to find results that can help with diagnosis and predicting outcomes. It may help by improving how clinicians identify the lymphoma type and forecast how it may behave.
This study looks for tumor “signatures” (including tiny RNA molecules, or miRNA) to predict outcomes in people with relapsed or resistant diffuse large B‑cell lymphoma (DLBCL). Your tissue samples help researchers see which patients may benefit from standard chemotherapy plus antibody treatment.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
This study looks at tiny molecules called microRNAs in the blood of people with either small testicular tumors (less than 2 cm) or leftover lymph node masses after chemotherapy for testicular cancer. The goal is to see if these microRNAs can help guide treatment decisions.
This study checks whether a blood-based test that looks at “RNA signals” can detect cancer. If you qualify, you may have extra blood taken to help test how accurate the method is.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.